Sepsis & infection

Circulating Cell-Free Mitochondrial DNA, Delirium, and Long-Term Cognitive Impairment in Critically Ill Adults With Sepsis: A Prospective Cohort Study

Crit Care MedPublished Multicenter, prospective cohort study

Main finding · DeliriumResult — go to the resultOdds ratio 0.93 95% CI 0.86–0.99

Authors' conclusion

In this multicenter, prospective cohort study, higher levels of ccf-mtDNA were associated with lower odds of delirium, a result that contradicted our hypothesis. This provocative finding should be interpreted cautiously until replicated and explained by future studies.

Study context

Population
Critically ill adults with sepsis plus shock and/or acute respiratory failure in medical and surgical ICUs in university and community hospitals in Nashville, TN
Participants
480 adults
Exposure
Individuals at the 75th percentile of circulating cell-free mitochondrial DNA (ccf-mtDNA) compared with those at the 25th percentile
Outcome
Delirium
Follow-up
During sepsis

Main finding

Delirium

Odds ratio

0.93

95% CI 0.86–0.99

P = 0.048

75th percentile of ccf-mtDNAvs 25th percentile of ccf-mtDNA
OR 0.93 (95% CI 0.86–0.99); P = 0.048

As reported in the abstract

Observational data: associations, not effects.

Further findings

In-hospital mortality

Hazard ratio (95% CI)P value
ccf-mtDNAMarginally associated1.09 (0.99–1.20)P = 0.08

Coma

OR (95% CI)P value
ccf-mtDNANot associated0.98 (0.90–1.05)P = 0.31

Cognitive outcomes (Repeatable Battery for the Assessment of Neuropsychological Status)

OutcomeBeta (95% CI)P value
3-monthNot associated0.23 (−1.58 to 2.05)P = 0.80
12-monthNot associated−0.36 (−2.13 to 1.42)P = 0.69

Original publication

Circulating Cell-Free Mitochondrial DNA, Delirium, and Long-Term Cognitive Impairment in Critically Ill Adults With Sepsis: A Prospective Cohort Study. Crit Care Med. Published 11 November 2026. doi:10.1097/ccm.0000000000007414

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.